Glomerulonefritis rápidamente progresiva mediada por inmunocomplejos (tipo II). Revisión de la literatura

Palabras clave: glomerulonefritis, complejos inmunes, nefropatía por inmunoglobulina A, púrpura de Schönlein-Henoch, insuficiencia renal terminal, biopsia, esteroides.

Resumen

La glomerulonefritis rápidamente progresiva mediada por complejos inmunes (GMNRP II) es un síndrome clínico caracterizado por el rápido deterioro de la función renal asociado a hematuria, edemas y oliguria. Histológicamente se manifiesta como una glomerulonefritis crescéntica, con la presencia de depósitos granulares en la inmunofluorescencia. Aunque es una enfermedad rara, es grave y puede evolucionar a una enfermedad renal crónica, por lo cual es fundamental su identificación temprana. A continuación, se presenta una revisión sobre este tipo de glomerulonefritis, con énfasis en su etiología y en las opciones terapéuticas existentes en la actualidad.

Descargas

La descarga de datos todavía no está disponible.

Biografía del autor/a

John Fredy Nieto-Ríos, Hospital Pablo Tobón Uribe, Universidad de Antioquia

Médico, Especialista en Medicina Interna, Especialista en Nefrología, Hospital Pablo Tobón Uribe, Universidad de Antioquia. Medellín, Colombia.
https://orcid.org/0000-0003-4781-3597

Miguel Bernardo Giraldo-Serna, Universidad de Antioquia

Médico, Residente de Medicina Interna, Universidad de Antioquia. Medellín Colombia.
https://orcid.org/0000-0002-1762-5520

Camilo Andrés García- Prada, Hospital Universitario San Vicente Fundación, IPS Sura

Médico, Especialista en Medicina Interna, Especialista en Nefrología, Hospital Universitario San Vicente Fundación, IPS Sura. Medellín, Colombia.

Andrés Felipe Lotero-Cadavid, Universidad Pontificia Bolivariana

Médico, Residente de Medicina Interna, Universidad Pontificia Bolivariana. Medellín, Colombia.
https://orcid.org/0000-0002-9855-5965

Lina María Serna-Higuita, Universidad de Tübingen

Médica, Especialista en Pediatría, Especialista en Nefrología Pediátrica, MSc en Epidemiología. Docente e Investigadora Asociada, Universidad de Tübingen. Tübingen, Alemania.
https://orcid.org/0000-0001-5182-8295

Luis F. Arias, Universidad de Antioquia

Médico, Especialista en Patología, PhD en Medicina. Docente, Universidad de Antioquia. Medellín, Colombia.
 https://orcid.org/0000-0001-5301-9264

Referencias bibliográficas

Ramos JM, Medina AB, Fernández MP. Glomerulonefritis agudas y rápidamente progresivas. Medicine 2019;12:4717-4724. https://doi.org/10.1016/j.med.2019.05.029.

Couser WG. Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy. Am J Kidney Dis 1988;11:449-464. https://doi.org/10.1016/s0272-6386(88)80079-9.

Parmar MS, Bashir K. Crescentric Glomerulonephritis. StatPearls. Treasure Island (FL): Stat-Pearls Publishing; 2021. Acceso 15 de abril de 2020. Disponible en https://www.ncbi.nlm.nih.gov/books/NBK430727/.

Sethi S, Haas M, Markowitz GS, D'Agati VD, Rennke HG, Jennette JC, et al. Mayo Clinic/Renal Pathology Society consensus report on pathologic classification, diagnosis, and reporting of GN. J Am Soc Nephrol 2016;27:1278-1287. https://doi.org/10.1681/asn.2015060612.

Appel G, Radhakrishnan J. Enfermedades glomerulares y síndromes nefróticos. In: Goldman L, Schaefer A, eds. Tratado de Medicina Interna. Ámsterdam, Países Bajos: Elsevier; 2016. p. 783-793.

Johnson R, Feehally J, Floege J, Tonelli M. Introduction to glomerular disease : Clinical pre sentations. Comprehensive Clinical Nephrology. Ámsterdam, Países Bajos: Elsevier; 2019. p. 184-198.

Praga-Terente M. Nefropatías glomerulares primarias. In: Rozman-Borstnar C, Cardellach-López F, eds. Medicina Interna. España: ACME Libreria Ciencia Medicina; 2020. p. 845-854.

Baldwin DS, Neugarten J, Feiner HD, GluckM, Spinowitz B. The existence of a protracted course in crescentic glomerulonephritis. Kidney Int 1987;31:790-794. https://doi.org/10.1038/ki.1987.67.

Moroni G, Ponticelli C. Rapidly progressive crescentic glomerulonephritis: Early treatment is a must. Autoimmun Rev 2014;13:723-729. https://doi.org/10.1016/j.autrev.2014.02.007.

Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int 2003;63:1164-1177. https://doi.org/10.1046/j.1523-1755.2003.00843.x.

Choudhury TA, Singh RG, Singh S, Singh TB, Rathore SS. Clinicopathologic spectrum of crescentic glomerulonephritis: a hospital-based study. Saudi J Kidney Dis Transpl 2014;25:689-696. https://doi.org/10.4103/1319-2442.132241.

Kidney Disease: Improving Global Outcomes (KDIGO). Chapter 10: Immunoglobulin A nephropathy. Kidney Int Suppl (2011) 2012;2:209-217. https://doi.org/10.1038/kisup.2012.23.

Aguiar A, Alvarer P, Paz-Wasiuchnik V, Abib A, Ciliberti E, Moretti L, et al. Glomerulonefritis rápidamente progresiva en ancianos. Medicina (Buenos Aires) 2013;73:148-152.

Wu T, Peng J, Meng T, Liu Q, Ao X, Lin W, et al. Clinicopathological features and prognostic analysis of 49 cases with crescentic glomerulonephritis. Exp Ther Med 2019;18:3984-3990. https://doi.org/10.3892/etm.2019.8023.

Chen M, Cui Z, Zhao MH. ANCA-associated vasculitis and anti-GBM disease: the experience in China. Nephrol Dial Transplant 2010;25:2062-2065. https://doi.org/10.1093/ndt/gfq134.

Bonsib SM. Glomerular basement membrane discontinuities. Scanning electron microscopic study of acellular glomeruli. Am J Pathol 1985;119:357-360.

Atkins RC, Nikolic-Paterson DJ, Song Q, Lan HY. Modulators of crescentic glomerulonephritis. J Am Soc Nephrol 1996;7:2271-2278. https://doi.org/10.1681/asn.V7112271.

Praga M, Gutierrez-Millet V, Navas JJ, Ruilope LM, Morales JM, Alcazar JM, et al. Acute worsening of renal function during episodes of macroscopic hematuria in IgA nephropathy. Kidney Int 1985;28:69-74. https://doi.org/10.1038/ki.1985.120.

Bennett WM, Kincaid-Smith P. Macroscopic hematuria in mesangial IgA nephropathy: correlation with glomerular crescents and renal dysfunction. Kidney Int 1983;23:393-400. https://doi.org/10.1038/ki.1983.32.

Arimura Y, Muso E, Fujimoto S, Hasegawa M, Kaname S, Usui J, et al. Evidence-based clinical practice guidelines for rapidly progressive glomerulonephritis 2014. Clin Exp Nephrol 2016;20:322-341. https://doi.org/10.1007/s10157-015-1218-8.

Bruns FJ, Adler S, Fraley DS, Segel DP. Longterm follow-up of aggressively treated idiopathic rapidly progressive glomerulonephritis. Am J Med 1989;86:400-406. https://doi.org/10.1016/0002-9343(89)90336-7.

Bagga A, Menon S. Rapidly progressive glomerulonephritis. In: Geary D, Schaefer F, eds. Comprehensive Pediatric Nephrology Mosby. 1st ed; 2008. p. 319-328.

Rodríguez-Iturbe B. Epidemic poststreptococcal glomerulonephritis. Kidney Int 1984;25:129- 136. https://doi.org/10.1038/ki.1984.19.

Nissenson AR, Baraff LJ, Fine RN, Knutson DW. Poststreptococcal acute glomerulonephritis: fact and controversy. Ann Intern Med 1979;91:76-86. https://doi.org/10.7326/0003-4819-91-1-76.

Blyth CC, Robertson PW, Rosenberg AR. Post-streptococcal glomerulonephritis in Sydney: a 16-year retrospective review. J Paediatr Child Health 2007;43:446-450. https://doi.org/10.1111/j.1440-1754.2007.01109.x.

Sanjad S, Tolaymat A, Whitworth J, Levin S. Acute glomerulonephritis in children: a review of 153 cases. South Med J 1977;70:1202-1206. https://doi.org/10.1097/00007611-197710000-00015.

Sagel I, Treser G, Ty A, Yoshizawa N, Kleinberger H, Yuceoglu AM, et al. Occurrence and nature of glomerular lesions after group Glomerulonefritis rápidamente progresiva mediada por inmunocomplejos (tipo II). A streptococci infections in children. Ann Intern Med 1973;79:492-499. https://doi.org/10.7326/0003-4819-79-4-492.

Gutiérrez E, González E, Hernández E, Morales E, Martínez MA, Usera G, et al. Factors that determine an incomplete recovery of renal function in macrohematuria-induced acute renal failure of IgA nephropathy. Clin J Am Soc Nephrol 2007;2:51-57. https://doi.org/10.2215/cjn.02670706.

Peru H, Soylemezoglu O, Bakkaloglu SA, Elmas S, Bozkaya D, Elmaci AM, et al. Henoch Schonlein purpura in childhood: clinical analysis of 254 cases over a 3-year period. Clin Rheumatol 2008;27:1087-1092. https://doi.org/10.1007/s10067-008-0868-2.

Trapani S, Micheli A, Grisolia F, Resti M, Chiappini E, Falcini F, et al. Henoch Schonlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. Semin Arthritis Rheum 2005;35:143-153. https://doi.org/10.1016/j.semarthrit.2005.08.007.

Peeters V, De Raeve L. Blistering eruptions in Henoch-Schönlein syndrome: more common than assumed. Eur J Pediatr 2018;177:475-476. https://doi.org/10.1007/s00431-017-2990-0.

Wu CS, Tung SY. Henoch-Schönlein purpura complicated by upper gastrointestinal bleeding with an unusual endoscopic picture. J Clin Gastroenterol 1994;19:128-131. https://doi.org/10.1097/00004836-199409000-00011.

Nathan K, Gunasekaran TS, Berman JH. Recurrent gastrointestinal Henoch-Schönlein purpura. J Clin Gastroenterol 1999;29:86-89. https://doi.org/10.1097/00004836-199907000-00022.

Johnson EF, Lehman JS, Wetter DA, Lohse CM, Tollefson MM. Henoch-Schönlein purpura and systemic disease in children: retrospective study of clinical findings, histopathology and direct immunofluorescence in 34 paediatric patients. Br J Dermatol 2015;172:1358-1363. https://doi.org/10.1111/bjd.13472.

Greenhall GH, Salama AD. What is new in the management of rapidly progressive glomerulonephritis? Clin Kidney J 2015;8:143-150. https://doi.org/10.1093/ckj/sfv008.

Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215-1226. https://doi.org/10.1002/art.34359.

Condon MB, Ashby D, Pepper RJ, Cook HT, Levy JB, Griffith M, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013;72:1280-1286. https://doi.org/10.1136/annrheumdis-2012-202844.

Ramos-Casals M, Diaz-Lagares C, Soto-Cardenas MJ, Brito-Zeron P, Cuadrado MJ, Sanna G, et al. Rituximab therapy in lupus nephritis: current clinical evidence. Clin Rev Allergy Immunol 2011;40:159-169. https://doi.org/10.1007/s12016-010-8205-3.

Tsanian M, Solov'ev SK, Torgashina AV, Aleksandrova EN, Radenska-Lopovok SG, Nikolaeva EV, et al. [Long-term follow-up of patients with refractory systemic lupus erythematosus during rituximab treatment]. Ter Arkh 2014;86:40-49.

Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, et al. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol 2017;28:1306-1313. https://doi.org/10.1681/asn.2016060640.

El-Husseini A, Ahmed A, Sabucedo A, Fabulo E. Refractory Henoch-Schönlein purpura: atypical aetiology and management. J Ren Care 2013;39:77-81. https://doi.org/10.1111/j.17556686.2013.12007.x.

Fenoglio R, Naretto C, Basolo B, Quattrocchio G, Ferro M, Mesiano P, et al. Rituximab therapy for IgA-vasculitis with nephritis: a case series and review of the literature. Immunol Res 2017;65:186-192. https://doi.org/10.1007/s12026-016-8827-5.

Chancharoenthana W, Townamchai N, Leelahavanichkul A, Wattanatorn S, Kanjanabuch T, Avihingsanon Y, et al. Rituximab for recurrent IgA nephropathy in kidney transplantation: A report of three cases and proposed mechanisms. Nephrology (Carlton) 2017;22:65-71. https://doi.org/10.1111/nep.12722.

Chen X, Chen N. Plasma exchange in the treatment of rapidly progressive glomerulonephritis. Contrib Nephrol 2013;181:240-247. https://doi.org/10.1159/000348632.

Appel GB, Waldman M. The IgA nephropathy treatment dilemma. Kidney Int 2006;69:1939-1944. https://doi.org/10.1038/sj.ki.5000434.

Barratt J, Feehally J. Treatment of IgA nephropathy. Kidney Int 2006;69:1934-1938. https://doi.org/10.1038/sj.ki.5000419.

Saulsbury FT. Henoch-Schönlein purpura in children. Report of 100 patients and review of the literature. Medicine (Baltimore) 1999;78:395-409. https://doi.org/10.1097/00005792-199911000-00005.

Cheigh JS, Kim H, Stenzel KH, Tapia L, Sullivan JF, Stubenbord W, et al. Systemic lupus erythematosus in patients with end-stage renal disease: long-term follow-up on the prognosis of patients and the evolution of lupus activity. Am J Kidney Dis 1990;16:189-195. https://doi.org/10.1016/s0272-6386(12)81017-1.

Chagnac A, Kiberd BA, Fariñas MC, Strober S, Sibley RK, Hoppe R, et al. Outcome of the acute glomerular injury in proliferative lupus nephritis. J Clin Invest 1989;84:922-930. https://doi.org/10.1172/jci114254.

Raff A, Hebert T, Pullman J, Coco M. Crescentic post-streptococcal glomerulonephritis with nephrotic syndrome in the adult: is aggressive therapy warranted? Clin Nephrol 2005;63:375-380. https://doi.org/10.5414/cnp63375.

Roy S 3rd, Murphy WM, Arant BS Jr. Poststreptococcal crescenteric glomerulonephritis in children: comparison of quintuple therapy versus supportive care. J Pediatr 1981;98:403-410. https://doi.org/10.1016/s0022-3476(81)80703-2.

Cómo citar
1.
Nieto-Ríos JF, Giraldo-Serna MB, García- Prada CA, Lotero-Cadavid AF, Serna-Higuita LM, Arias LF. Glomerulonefritis rápidamente progresiva mediada por inmunocomplejos (tipo II). Revisión de la literatura. Med. Lab. [Internet]. 8 de julio de 2021 [citado 8 de diciembre de 2021];25(3):569-80. Disponible en: https://medicinaylaboratorio.com/index.php/myl/article/view/449
Publicado
2021-07-08
Sección
Artículos de revisión
Crossref Cited-by logo

Más sobre este tema

Artículos más leídos del mismo autor/a